What is adcendo?
Adcendo ApS is a biotechnology firm specializing in the development of novel antibody-drug conjugates (ADCs) targeting cancer forms with significant unmet medical needs. The company's approach centers on ADCs directed at novel targets that are overexpressed across various cancer types. This strategic focus positions Adcendo to address critical gaps in current treatment options, leveraging advanced scientific research to create next-generation therapies.
How much funding has adcendo raised?
adcendo has raised a total of $62M across 1 funding round:
Series A
$62M
Series A (2021): $62M with participation from GlideNet Healthcare, RA Capital Management, HealthCap, and Novo Seeds
Key Investors in adcendo
GlideNet Healthcare
GlideNet Healthcare is a service provider focused on helping healthcare clients achieve financial goals through value assessment and program execution, primarily serving hospital systems in the United States.
RA Capital Management
RA Capital Management is an investment manager focused on public and private healthcare and life science companies, including drug development, medical devices, and diagnostics, with a growing interest in climate technologies.
HealthCap
HealthCap USA provides liability insurance and risk management services exclusively for senior living communities, focusing on quality care and risk reduction.
What's next for adcendo?
With the recent influx of major strategic investment, Adcendo is poised for accelerated growth and the advancement of its drug development pipeline. The substantial capital infusion, totaling $62M, will likely fuel further research and development, clinical trials, and potential expansion of its operational capabilities. This backing signifies strong investor confidence in Adcendo's therapeutic approach and its potential to make a significant impact on cancer treatment.
See full adcendo company page
